tetano
Editor, Senior Moderator
J Orthop Res
. 2023 Feb 22.
doi: 10.1002/jor.25537. Online ahead of print.
Acute Bone Loss Following SARS-CoV-2 Infection in Mice
Anne K Haudenschild[SUP] 1 [/SUP], Blaine A Christiansen[SUP] 1 [/SUP], Sophie Orr[SUP] 1 [/SUP], Erin E Ball[SUP] 2 [/SUP], Christopher M Weiss[SUP] 3 [/SUP], Hongwei Liu[SUP] 3 [/SUP], David P Fyhrie[SUP] 1 [/SUP], Jasper H N Yik[SUP] 1 [/SUP], Lark L Coffey[SUP] 2 [/SUP], Dominik R Haudenschild[SUP] 1 [/SUP]
Affiliations
Abstract
The novel coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) and has infected more than 650 million people worldwide. Approximately 23% of these patients developed lasting "long-haul" COVID symptoms, including fatigue, joint pain, and systemic hyperinflammation. However, the direct clinical impact of SARS-CoV-2 infection on the skeletal system including bone and joint health has not been deter- mined. Utilizing a humanized mouse model of COVID-19, this study provides the first direct evidence that SARS-CoV- 2 infection leads to acute bone loss, increased osteoclast number, and thinner growth plates. This bone loss could decrease whole-bone mechanical strength and increase the risk of fragility fractures, particularly in older patients, while thinner growth plates may create growth disturbances in younger patients. Evaluating skeletal health in patients that have recovered from COVID-19 will be crucial to identify at-risk populations and develop effective countermeasures. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Growth Plate; Osteoclasts; SARS-CoV-2; post-acute COVID-19 syndrome.
. 2023 Feb 22.
doi: 10.1002/jor.25537. Online ahead of print.
Acute Bone Loss Following SARS-CoV-2 Infection in Mice
Anne K Haudenschild[SUP] 1 [/SUP], Blaine A Christiansen[SUP] 1 [/SUP], Sophie Orr[SUP] 1 [/SUP], Erin E Ball[SUP] 2 [/SUP], Christopher M Weiss[SUP] 3 [/SUP], Hongwei Liu[SUP] 3 [/SUP], David P Fyhrie[SUP] 1 [/SUP], Jasper H N Yik[SUP] 1 [/SUP], Lark L Coffey[SUP] 2 [/SUP], Dominik R Haudenschild[SUP] 1 [/SUP]
Affiliations
- PMID: 36815216
- DOI: 10.1002/jor.25537
Abstract
The novel coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) and has infected more than 650 million people worldwide. Approximately 23% of these patients developed lasting "long-haul" COVID symptoms, including fatigue, joint pain, and systemic hyperinflammation. However, the direct clinical impact of SARS-CoV-2 infection on the skeletal system including bone and joint health has not been deter- mined. Utilizing a humanized mouse model of COVID-19, this study provides the first direct evidence that SARS-CoV- 2 infection leads to acute bone loss, increased osteoclast number, and thinner growth plates. This bone loss could decrease whole-bone mechanical strength and increase the risk of fragility fractures, particularly in older patients, while thinner growth plates may create growth disturbances in younger patients. Evaluating skeletal health in patients that have recovered from COVID-19 will be crucial to identify at-risk populations and develop effective countermeasures. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Growth Plate; Osteoclasts; SARS-CoV-2; post-acute COVID-19 syndrome.